Breaking newsCOVID-19
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
The authors of this study report the safety and immunogenicity of heterologous schedules with the ChAd and BNT vaccines.